There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Avid Bioservices (CDMO – Research Report) and LifeMD (LFMD – Research Report) with bullish sentiments.
Avid Bioservices (CDMO)
In a report released today, Matt Hewitt from Craig-Hallum assigned a Buy rating to Avid Bioservices. The company’s shares closed last Monday at $6.80.
According to TipRanks.com, Hewitt is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Avid Bioservices with a $9.50 average price target.
See the top stocks recommended by analysts >>
LifeMD (LFMD)
In a report released today, Aaron Spychalla from Craig-Hallum assigned a Buy rating to LifeMD. The company’s shares closed last Monday at $9.61.
According to TipRanks.com, Spychalla is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for LifeMD with a $12.00 average price target, a 24.4% upside from current levels. In a report issued on April 12, B.Riley Financial also reiterated a Buy rating on the stock with a $12.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CDMO:
- Avid Bioservices management to meet with Craig Hallum
- Avid Bioservices announces receipt of deficiency notice from Nasdaq
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q
- Avid Bioservices to delay 10-Q filing, must restate Q3 financials
- Avid Bioservices price target lowered to $12 from $15 at Stephens
